UroGen Pharma (NASDAQ:URGN) Receives Outperform Rating from Oppenheimer

Oppenheimer reissued their outperform rating on shares of UroGen Pharma (NASDAQ:URGN) in a research note issued to investors on Wednesday, Benzinga reports. Oppenheimer currently has a $40.00 target price on the stock.

Several other brokerages have also commented on URGN. EF Hutton Acquisition Co. I upgraded UroGen Pharma to a “strong-buy” rating in a research report on Monday, October 14th. Guggenheim started coverage on shares of UroGen Pharma in a report on Thursday, August 22nd. They set a “buy” rating and a $40.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price target on shares of UroGen Pharma in a report on Tuesday, October 15th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $48.38.

UroGen Pharma Stock Down 0.9 %

Shares of NASDAQ URGN opened at $12.73 on Wednesday. The company has a current ratio of 8.15, a quick ratio of 7.93 and a debt-to-equity ratio of 3.23. UroGen Pharma has a 12-month low of $10.60 and a 12-month high of $20.70. The company has a market cap of $298.57 million, a P/E ratio of -3.74 and a beta of 1.11. The stock has a fifty day moving average price of $13.44 and a 200 day moving average price of $14.35.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.09). The business had revenue of $21.85 million during the quarter, compared to the consensus estimate of $23.69 million. Research analysts anticipate that UroGen Pharma will post -3.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP increased its stake in UroGen Pharma by 49.3% during the 4th quarter. Wellington Management Group LLP now owns 104,600 shares of the company’s stock valued at $1,569,000 after buying an additional 34,537 shares during the period. Oak Ridge Investments LLC bought a new stake in UroGen Pharma in the first quarter worth about $918,000. BNP Paribas Financial Markets lifted its holdings in UroGen Pharma by 73.1% in the 1st quarter. BNP Paribas Financial Markets now owns 39,795 shares of the company’s stock valued at $597,000 after acquiring an additional 16,799 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of UroGen Pharma by 14.3% during the 1st quarter. Vanguard Group Inc. now owns 194,966 shares of the company’s stock valued at $2,924,000 after purchasing an additional 24,367 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD acquired a new position in shares of UroGen Pharma in the 1st quarter worth approximately $4,008,000. Institutional investors and hedge funds own 91.29% of the company’s stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.